Actinium Pharmaceuticals Inc
actiniumpharma.comWhat Do They Do?
Develops targeted radiotherapy drug candidates for solid tumors and blood cancers, plus conditioning agents for bone marrow transplants and cell and gene therapies.
10-K for FY2025, filed Mar 30, 2026
How Do They Make Money?
A National Institutes of Health grant supports an Iomab-ACT study with Memorial Sloan Kettering; Iomab-B licensing brought an upfront payment and may bring regulatory and sales milestones and royalties on net sales.
10-K for FY2025, filed Mar 30, 2026
$90K
-
10-K for FY2025, filed Mar 30, 2026
$90K ↗
Who Are Their Customers?
Immedica licensed exclusive Iomab-B commercialization rights in certain countries in Europe, the Middle East and North Africa. A National Institutes of Health grant supports an Iomab-ACT study with Memorial Sloan Kettering Cancer Center.
10-K for FY2025, filed Mar 30, 2026 10-K for FY2022, filed Mar 31, 2023On April 12, 2022, we announced a commercialization agreement for Iomab-B with Immedica AB (“Immedica”) for exclusive rights in Europe, the…View ↗
Do Revenues Turn Into Profits?
No. It lost $33.9M in FY2025.
How Are They Changing?
-
Aug 14, 2026
NYSE American accepts listing compliance plan
The shares remain listed during the plan period through November 27, 2027; delisting proceedings may follow if the company does not regain compliance.
Sources
8-K, filed Aug 14, 2026
On August 12, 2026, the Company received a letter from NYSE Regulation stating that it had reviewed and accepted the Company’s compliance…View ↗
Shrinking. Revenue fell 92% in 4 years, from $1.1M in FY2021 to $90K in FY2025, about 47% a year.
Partnerships for hematology programs
The earlier report planned to commercialize Iomab-B in the United States and launch Actimab-A. The latest report says the company is seeking partners to advance both hematology programs while preserving meaningful economics.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 30, 2026
Broader tumor focus
The earlier report centers on Iomab-B and Actimab-A for relapsed or refractory AML, with Iomab-ACT for cell and gene therapy conditioning. The latest report also foregrounds a solid-tumor program and Actimab-A in solid tumors as well as blood cancers.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 30, 2026Actinium Pharmaceuticals, Inc. (“Actinium”) is a biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing…View ↗
We also intend during this time frame to further advance Iomab-B outside of acute myeloid leukemia (“AML”) based on promising data as a…View ↗
Our Iomab-B and Actimab-A product candidates fill the major unmet medical needs in r/r AML in a complementary fashion as they are directed…View ↗
Since our inception, we have focused on developing innovative and differentiated radiotherapies. Our pipeline of both early and later stage…View ↗
Who Do They Compete With?
Competes with AstraZeneca and Johnson & Johnson
10-K for FY2025, filed Mar 30, 2026EGFR-mutant NSCLC represents approximately 30,000 U.S. patients annually, with current treatment dominated by AstraZeneca’s Tagrisso®…View ↗
Loading...
